Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration

PALATIN TECHNOLOGIES INC

Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.
Collaboration, announced Aug 18, 2025, targets first-in-class melanocortin receptor treatment for diabetic retinopathy and diabetic macular edema.
Palatin eligible for up to €278M ($328M) in success-based milestones plus tiered royalties on net sales from the collaboration.
Upfront payment of €2M already received; total near-term research milestones of €18M including the €5.5M achieved.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.